1-3 of 3
Charlene Audette
Close
Sort by
Journal Articles

CD123 Expression Patterns and Potential of IMGN632, a CD123-Targeted Antibody Drug Conjugate, in Acute Lymphoblastic Leukemia

Evgeniya Angelova, MD PhD, Charlene Audette, Yelena Kovtun, PhD, Naval Daver, MD, Sa A. Wang, MD, Sherry Pierce, BSN, BA, Sergej Naumovich Konoplev, MD PhD, Jeffrey L. Jorgensen, MD PhD, Marina Konopleva, MD PhD, Patrick A. Zweidler-McKay, MDPhD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Joseph David Khoury, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2718.
https://doi.org/10.1182/blood.V130.Suppl_1.2718.2718
Published: 2017
Journal Articles

A CD123-Targeting Antibody-Drug Conjugate (ADC), IMGN632, Designed to Eradicate Acute Myeloid Leukemia (AML) Cells While Sparing Normal Bone Marrow Cells

Yelena Kovtun, PhD, Gregory Jones, Charlene Audette, Lauren Harvey, MS, Baudouin Gerard, PhD, Alan Wilhelm, Chen Bai, Sharlene Adams, PhD, Victor S Goldmacher, PhD, Ravi Chari, PhD, Thomas Chittenden, PhD
Journal: Blood
Blood (2016) 128 (22): 768.
https://doi.org/10.1182/blood.V128.22.768.768
Published: 2016
Journal Articles

IMGN779, a CD33-Targeted Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Effector Molecule, Induces DNA Damage, Cell Cycle Arrest, and Apoptosis in AML Cells

Watkins M Krystal, MS, Russell Walker, MS, Nathan Fishkin, PhD, Charlene Audette, Yelena Kovtun, PhD, Angela Romanelli, PhD
Journal: Blood
Blood (2015) 126 (23): 1366.
https://doi.org/10.1182/blood.V126.23.1366.1366
Published: 2015